Exclusive Summary

• - Fully off-patent globally and US-registered high-strength oral suspension (200mg/5ml, 35ml) enables rapid multi-country distribution.
• - Clear demand in high-burden populations: ~39 million people living with HIV, ~223,000 annual cryptococcal meningitis cases, and millions of oral/esophageal candidiasis episodes.
• - Included in WHO Model List of Essential Medicines and international guidelines as first-line for mucosal candidiasis and a core drug for cryptococcal consolidation/maintenance.
• - Despite broad generic competition, high-strength suspension suppliers are fewer; the 40 mg/ml format minimizes dose volume (10–20 ml/day for 400–800 mg) for dysphagia and tube-feeding patients.
• - US registration and compliance credentials plus significant cost savings versus originator support tender and distribution-focused partnerships.